Breaking News, Financial News

Financial Report: InterMune

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune 2Q Revenues: $24.1 million (-10%) 2Q Loss: $44 million* (loss of $23.7 million in 2Q2005) YTD Revenues: $48.5 million (-12%) YTD Loss: $56.8 million (loss of 41.1 million YTD2005) Comments: Revenues for the quarter were comprised solely of Actimmune sales. 2Q2005 revenues consisted of Actimmune and Aralast sales. The company stopped co-promoting Aralast in December 2005. R&D expense for quarter was $24.8 million, up 38% *Results for the quarter include a ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters